Why the study?
Do thrombolysis and discharge medications (beta-blockers, antiplatelets, calcium channel blockers) improve long-term survival in non-diabetic patients surviving a first Q wave acute myocardial infarction?
Do thrombolysis and discharge medications (beta-blockers, antiplatelets, calcium channel blockers) improve long-term survival in non-diabetic patients surviving a first Q wave acute myocardial infarction?
In post-myocardial infarction patients, beta-blockers and antiplatelets are associated with improved long-term survival, while calcium channel blockers, particularly diltiazem, may increase mortality risk.
No takes yet. Share an insight, caveat, or question.
Supports beta-blocker and antiplatelet associations with lower post-MI mortality but cautions on diltiazem; leaves open causal confirmation in trials.
Köenig et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: